We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Name | Symbol | Market | Type |
|---|---|---|---|
| GSK plc | NYSE:GSK | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.24 | -0.60% | 39.77 | 40.005 | 39.49 | 39.97 | 4,915,985 | 21:00:03 |
From Jul 2019 to Jul 2024
By Michael Dabaie
GlaxoSmithKline PLC said the U.S. Food and Drug Administration approved Benlysta for adult patients with active lupus nephritis receiving standard therapy.
The approval extends the current indication in the U.S. to include both systemic lupus erythematosus and lupus nephritis for the intravenous and subcutaneous formulations.
Lupus nephritis is a serious inflammation of the kidneys caused by systemic lupus erythematosus, the most common form of lupus, which can lead to end-stage kidney disease, requiring dialysis or a kidney transplant, the company said.
GlaxoSmithKline American depositary receipts were up 1.8% to $37.55 premarket Thursday.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
December 17, 2020 09:42 ET (14:42 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year GSK Chart |
1 Month GSK Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
